Arylazolylthioacetanilide. Part 8 *: Design, synthesis and biological evaluation of Novel 2-(2-(2,4-Dichlorophenyl)-2H-1,2,4-triazol-3- ylthio)-N-arylacetamides As Potent HIV-1 inhibitors

European Journal of Medicinal Chemistry

Volumn 46, Issue 10, 2011, Pages 5039-5045

  Zhan, Peng ^a   Chen, Xuwang ^a   Li, Xiao ^a   Li, Dongyue ^a   Tian, Ye ^a   Chen, Wenwen ^a   Pannecouque, Christophe ^b   De Clercq, Erik ^b   Liu, Xinyong ^a  

^a SHANDONG UNIVERSITY   (China)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

1,2,4 Triazole; Bioactivity; HIV; NNRTIs; SAR; Synthesis

Indexed keywords

1,2,4 TRIAZOLACETAMIDE; 2 (2 (2,4 DICHLOROPHENYL) 2H 1,2,4 TRIAZOL 3 YLTHIO) N ARYLACETAMIDE; 2 [2 (2,4 DICHLOROPHENYL) 2H 1,2,4 TRIAZOL 3 YLTHIO] N (2 FLUOROPHENYL)ACETAMIDE; 2 [2 (2,4 DICHLOROPHENYL) 2H 1,2,4 TRIAZOL 3 YLTHIO] N (2 NITROPHENYL)ACETAMIDE; 2 [2 (2,4 DICHLOROPHENYL) 2H 1,2,4 TRIAZOL 3 YLTHIO] N (4 METHYL 2 NITROPHENYL)ACETAMIDE; 2 [2 (2,4 DICHLOROPHENYL) 2H 1,2,4 TRIAZOL 3 YLTHIO] N O TOLYLACETAMIDE; ACETAMIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DELAVIRDINE; DIDEOXYCITIDINE; EFAVIRENZ; ETHYL 3 BROMO 4 [2 [2 (2,4 DICHLOROPHENYL) 2H 1,2,4 TRIAZOL 3 YLTHIO]ACETAMIDO]BENZOATE; ETHYL 4 [2 [2 (2,4 DICHLOROPHENYL) 2H 1,2,4 TRIAZOL 3 YLTHIO]ACETAMIDO]BENZOATE; ETRAVIRINE; METHYL 3 BROMO 4 [2 [2 (2,4 DICHLOROPHENYL) 2H 1,2,4 TRIAZOL 3 YLTHIO]ACETAMIDO]BENZOATE; METHYL 4 [2 [2 (2,4 DICHLOROPHENYL) 2H 1,2,4 TRIAZOL 3 YLTHIO]ACETAMIDO]BENZOATE; N (2 BROMO 4 CHLOROPHENYL) 2 [2 (2,4 DICHLOROPHENYL) 2H 1,2,4 TRIAZOL 3 YLTHIO]ACETAMIDE; N (2 BROMO 4 METHYLPHENYL) 2 [2 (2,4 DICHLOROPHENYL) 2H 1,2,4 TRIAZOL 3 YLTHIO]ACETAMIDE; N (2 BROMOPHENYL) 2 [2 (2,4 DICHLOROPHENYL) 2H 1,2,4 TRIAZOL 3 YLTHIO]ACETAMIDE; N (2 CHLOROPHENYL) 2 [2 (2,4 DICHLOROPHENYL) 2H 1,2,4 TRIAZOL 3 YLTHIO)ACETAMIDE; N (2 CHLOROPYRIDIN 3 YL) 2 [2 (2,4 DICHLOROPHENYL) 2H 1,2,4 TRIAZOL 3 YLTHIO]ACETAMIDE; N (2,4 DICHLOROPHENYL) 2 [2 (2,4 DICHLOROPHENYL) 2H 1,2,4 TRIAZOL 3 YLTHIO]ACETAMIDE; N (4 ACETYL 2 BROMOPHENYL) 2 [2 (2,4 DICHLOROPHENYL) 2H 1,2,4 TRIAZOL 3 YLTHIO]ACETAMIDE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN;

ACETAMIDES; ANTI-HIV AGENTS; CELL LINE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HIV-2; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES; VIRUS REPLICATION;

EID: 80053197763     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.08.011     Document Type: Article

References (37)

1. AIDS Epidemic Update: December 2009, UNAIDS/WHO, http://www.unaids.org.
2. E. De Clercq Int. J. Biochem. Cell Biol. 36 2004 1800 1822
3. E. De Clercq Curr. Opin. Pharmacol. 10 2010 507 515
4. S.G. Sarafianos, B. Marchand, and K. Das J. Mol. Biol. 385 2009 693 713
5. P. Zhan, X. Liu, and Z. Li Curr. Med. Chem. 16 2009 2876 2889
6. P. Zhan, X. Liu, and Z. Li Curr. Med. Chem. 16 2009 3903 3917
7. P. Zhan, X. Chen, D. Li, et al., HIV-1 NNRTIs: structural diversity, pharmacophore similarity and implications for drug design. Med. Res. Rev. 2011 Apr 26. doi: 10.1002/med.20241.
8. P. Zhan, X. Liu, Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors: a patent review. Expert Opin Ther Pat. 21 (2011) 717 - 796. (invited review).
9. P. Zhan, D. Li, and X. Chen Curr. Med. Chem. 18 2011 29 46
10. P. Zhan, Z. Li, and X. Liu Mini. Rev. Med. Chem. 9 2009 1014 1023
11. Z. Wang, B. Wu, and K.L. Kuhen Bioorg. Med. Chem. Lett. 16 2006 4174 4177
12. M. De La Rosa, H.W. Kim, and E. Gunic Bioorg. Med. Chem. Lett. 16 2006 4444 4449
13. E. Muraglia, O.D. Kinzel, and R. Laufer Bioorg. Med. Chem. Lett. 16 2006 2748 2752
14. J.A. O'Meara, A. Jakalian, and S. LaPlante Bioorg. Med. Chem. Lett. 17 2007 3362 3366
15. A. Gagnon, M.H. Amad, and P.R. Bonneau Bioorg. Med. Chem. Lett. 17 2007 4437 4441
16. A. Gagnon, S. Landry, and R. Coulombe Bioorg. Med. Chem. Lett. 19 2009 1199 1205
17. Z. Zhang, W. Xu, and Y.H. Koh Antimicrob. Agents Chemother. 51 2007 429 437
18. G. Moyle, M. Boffito, and A. Stoehr Antimicrob. Agents Chemother. 54 2010 3170 3178
19. P. Zhan, X. Liu, and Y. Cao Bioorg. Med. Chem. Lett. 18 2008 5368 5371
20. P. Zhan, X. Liu, and Z. Li Bioorg. Med. Chem. 17 2009 5920 5927
21. P. Zhan, X. Liu, and Z. Fang Eur. J. Med. Chem. 44 2009 4648 4653
22. P. Zhan, X. Liu, and Z. Li Chem. Biodivers 7 2010 1717 1727
23. P. Zhan, X. Liu, and J. Zhu Bioorg. Med. Chem. 17 2009 5775 5781
24. P. Zhan, X. Liu, and Z. Fang Bioorg. Med. Chem. 17 2009 6374 6379
25. P. Zhan, H. Liu, and X. Liu Med. Chem. Res. 19 2009 652 663
26. G.A. Patani, and E.J. LaVoie Chem. Rev. 96 1996 3147 3176
27. P.H. Olesen Curr. Opin. Drug Discov. Devel 4 2001 471 478
28. L.M. Lima, and E.J. Barreiro Curr. Med. Chem. 12 2005 23 49
29. J.W. Lyga Synth. Commun. 16 1986 163 167
30. L.T. Bacheler Drug Resist. Updates 2 1999 56 67
31. R. Pauwels, J. Balzarini, and M. Baba J. Virol. Methods 20 1988 309 321
32. C. Pannecouque, D. Daelemans, and E. De Clercq Nat. Protoc. 3 2008 427 434
33. M. Popovic, M.G. Sarngadharan, and E. Read Science 224 1984 497 500
34. F. Barr-Sinoussi, J.C. Chermann, and F. Rey Science 220 1983 868 871
35. I. Miyoshi, H. Taguchi, and I. Kobonishi Gann. Monogr. 28 1982 219 228
36. K. Suzuki, B.P. Craddock, and N. Okamoto J. Virol. Methods 44 1993 189 198
37. J. Wu, X. Liu, and X. Cheng Molecules 12 2007 2003 2016